Compare Sana Biotechnology Inc (SANA) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs STMicroelectronics NV — how do they compare? Sana Biotechnology Inc trades at $2.8 (market cap $836.71M), while STMicroelectronics NV trades at $52.03 (market cap $48.14B). The key difference: STMicroelectronics NV is far larger — about 57.5× Sana Biotechnology Inc's market cap, and STMicroelectronics NV pays a 0.68% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and STMicroelectronics NV for 64 Days on average.
| SANA | STM | |
|---|---|---|
Market Cap | $836.71M | $48.14B |
Volume | 4,507,444 | 9,776,015 |
Sector | Health | Technology |
52-Week High | $5.92 | $79.91 |
52-Week Low | $2.68 | $21.20 |
Typical Hold Time | 23 Days | 64 Days |
Enterprise Value | $749.96M | $45.66B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
STM is trading at $52.06, down 7.33% over 24 hours amid broader tech sector pressure. The stock shows mixed signals with a bearish technical outlook but positive analyst sentiment, including a $77.31 consensus price target. Recent earnings have been volatile with two misses and one beat in the last three quarters, while the company maintains strong cash flow generation of $555 million in 2025. STM is positioning for AI data-center revenue growth, targeting over $2 billion by 2027, with recent product launches in automotive imaging and edge AI partnerships.
The outlook remains cautiously optimistic given STM's strategic positioning in AI infrastructure and automotive semiconductors, though near-term margin pressures from facility transitions and competitive dynamics pose risks. The 48% upside to consensus target suggests Wall Street sees recovery potential, but investors should monitor execution on AI revenue targets and margin improvement through 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
